Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
2023 · Diabetologia · 95 citations
https://doi.org/10.1007/s00125-023-06053-9